Profiel
Robert L.
Simon formerly worked at Bristol Myers Squibb Co., as Vice President-Worldwide Regulatory Affairs from 1987 to 2000, Gilead Sciences, Inc., as Vice President-Global Regulatory Affairs from 2000 to 2001, OSI Pharmaceuticals, Inc., as EVP-Pharmaceutical Development & Manufacturing, and Threshold Pharmaceuticals, Inc., as SVP-Regulatory Affairs & Quality Assurance.
Mr. Simon received his undergraduate degree from San Jose State University.
Eerdere bekende functies van Robert L. Simon
| Bedrijven | Functie | Einde |
|---|---|---|
| GILEAD SCIENCES, INC. | General Counsel | 01-12-2001 |
| BRISTOL-MYERS SQUIBB COMPANY | General Counsel | 01-07-2000 |
Threshold Pharmaceuticals, Inc.
 Threshold Pharmaceuticals, Inc. BiotechnologyHealth Technology Threshold Pharmaceuticals, Inc. engages in the development of therapeutics for treating tumors. It offers the Evofosfamide which designed as a prodrug that is activated under the extreme hypoxic conditions commonly found in tumors, but not typically in healthy tissues, and TH-3424 which is a small-molecule drug candidate for the treatment of liver, castrate resistant prostate cancer, T-cell acute lymphoblastic leukemias, and other cancers. The company was founded by Jeffrey W. Bird on October 17, 2001 and is headquartered in South San Francisco, CA | General Counsel | - |
| OSI PHARMACEUTICALS, INC. | Corporate Officer/Principal | - |
Opleiding van Robert L. Simon
| San Jose State University | Undergraduate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 2 |
|---|---|
| BRISTOL-MYERS SQUIBB COMPANY | Health Technology |
| GILEAD SCIENCES, INC. | Health Technology |
| Bedrijven in privébezit | 2 |
|---|---|
OSI Pharmaceuticals, Inc.
 OSI Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology OSI Pharmaceuticals, Inc. manufactured and develope dpharmaceutical drugs. The company was founded in 1983 and was headquartered in Farmingdale, NY. | Health Technology |
Threshold Pharmaceuticals, Inc.
Threshold Pharmaceuticals, Inc. BiotechnologyHealth Technology Threshold Pharmaceuticals, Inc. engages in the development of therapeutics for treating tumors. It offers the Evofosfamide which designed as a prodrug that is activated under the extreme hypoxic conditions commonly found in tumors, but not typically in healthy tissues, and TH-3424 which is a small-molecule drug candidate for the treatment of liver, castrate resistant prostate cancer, T-cell acute lymphoblastic leukemias, and other cancers. The company was founded by Jeffrey W. Bird on October 17, 2001 and is headquartered in South San Francisco, CA | Health Technology |
